Quantum Computing Inc. and Sanders TDI: A Strategic Partnership for Drug Discovery

Quantum Computing Inc. (QCi), a leading innovator in integrated photonics and quantum optics technology, has announced a strategic collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI). This partnership aims to advance computational biomedicine research by leveraging QCi's quantum computation technology and hardware, specifically the Dirac-3 Entropy Quantum Computing Machine. Sanders TDI, a non-profit drug discovery institute based in New York City, will utilize QCi's quantum computation technology for experimental work, focusing on computational chemistry research and biomolecular modeling.



As part of the collaboration, QCi will offer Sanders TDI cloud-based access to its Dirac-3 systems, which operate at room temperature and low power. These systems are designed to solve complex optimization problems, making them an ideal tool for drug discovery and computational biomedicine. The partnership will focus on advancing Sanders TDI's computational chemistry research by leveraging quantum technologies, including quantum analog computers, for proof of concept calculations in biomolecular modeling.

The collaboration between QCi and Sanders TDI represents a significant step forward in the application of quantum computing to the pharmaceutical industry. By utilizing QCi's room-temperature quantum systems, Sanders TDI can explore a diverse set of potential use cases in computational chemistry and biomolecular modeling. This partnership positions QCi's Dirac-3 quantum computing platform for real-world applications in drug discovery and computational biomedicine, while also validating the technology in a practical, revenue-generating application.

In conclusion, the strategic collaboration between Quantum Computing Inc. and Sanders Tri-Institutional Therapeutics Discovery Institute is a promising development in the field of computational biomedicine. By leveraging QCi's quantum computation technology and hardware, Sanders TDI can advance its computational chemistry research and explore the potential of quantum-enabled applications in drug discovery. This partnership not only validates QCi's technology in a real-world application but also opens doors to the lucrative pharmaceutical research market, positioning the company for long-term growth and success.